217 related articles for article (PubMed ID: 34432120)
1. Predicting the in vivo developmental toxicity of benzo[a]pyrene (BaP) in rats by an in vitro-in silico approach.
Wang D; Rietdijk MH; Kamelia L; Boogaard PJ; Rietjens IMCM
Arch Toxicol; 2021 Oct; 95(10):3323-3340. PubMed ID: 34432120
[TBL] [Abstract][Full Text] [Related]
2. Understanding the linked kinetics of benzo(a)pyrene and 3-hydroxybenzo(a)pyrene biomarker of exposure using physiologically-based pharmacokinetic modelling in rats.
Heredia-Ortiz R; Bouchard M
J Pharmacokinet Pharmacodyn; 2013 Dec; 40(6):669-82. PubMed ID: 24166060
[TBL] [Abstract][Full Text] [Related]
3. Modeling of the internal kinetics of benzo(a)pyrene and 3-hydroxybenzo(a)pyrene biomarker from rat data.
Heredia-Ortiz R; Bouchard M; Marie-Desvergne C; Viau C; Maître A
Toxicol Sci; 2011 Aug; 122(2):275-87. PubMed ID: 21613232
[TBL] [Abstract][Full Text] [Related]
4. A toxicokinetic study to elucidate 3-hydroxybenzo(a)pyrene atypical urinary excretion profile following intravenous injection of benzo(a)pyrene in rats.
Marie C; Bouchard M; Heredia-Ortiz R; Viau C; Maître A
J Appl Toxicol; 2010 Jul; 30(5):402-10. PubMed ID: 20186696
[TBL] [Abstract][Full Text] [Related]
5. Use of physiologically-based pharmacokinetic modeling to simulate the profiles of 3-hydroxybenzo(a)pyrene in workers exposed to polycyclic aromatic hydrocarbons.
Heredia Ortiz R; Maître A; Barbeau D; Lafontaine M; Bouchard M
PLoS One; 2014; 9(7):e102570. PubMed ID: 25032692
[TBL] [Abstract][Full Text] [Related]
6. 3-Hydroxybenzo(a)pyrene as a biomarker of dermal exposure to benzo(a)pyrene.
Payan JP; Lafontaine M; Simon P; Marquet F; Champmartin-Gendre C; Beydon D; Wathier L; Ferrari E
Arch Toxicol; 2009 Sep; 83(9):873-83. PubMed ID: 19526226
[TBL] [Abstract][Full Text] [Related]
7. Predicting lung dosimetry of inhaled particleborne benzo[a]pyrene using physiologically based pharmacokinetic modeling.
Campbell J; Franzen A; Van Landingham C; Lumpkin M; Crowell S; Meredith C; Loccisano A; Gentry R; Clewell H
Inhal Toxicol; 2016 Sep; 28(11):520-35. PubMed ID: 27569524
[TBL] [Abstract][Full Text] [Related]
8. Urinary excretion kinetics of pyrene and benzo(a)pyrene metabolites following intravenous administration of the parent compounds or the metabolites.
Bouchard M; Viau C
Toxicol Appl Pharmacol; 1996 Aug; 139(2):301-9. PubMed ID: 8806846
[TBL] [Abstract][Full Text] [Related]
9. Integrating in vitro data and physiologically based kinetic (PBK) modelling to assess the in vivo potential developmental toxicity of a series of phenols.
Strikwold M; Spenkelink B; de Haan LHJ; Woutersen RA; Punt A; Rietjens IMCM
Arch Toxicol; 2017 May; 91(5):2119-2133. PubMed ID: 27815601
[TBL] [Abstract][Full Text] [Related]
10. Physiologically-based pharmacokinetic modeling of benzo(a)pyrene and the metabolite in humans of different ages.
Deng L; Liu H; Deng Q
Int J Environ Health Res; 2021 Mar; 31(2):202-214. PubMed ID: 31296039
[TBL] [Abstract][Full Text] [Related]
11. Comparison of the kinetics of various biomarkers of benzo[a]pyrene exposure following different routes of entry in rats.
Moreau M; Bouchard M
J Appl Toxicol; 2015 Jul; 35(7):781-90. PubMed ID: 25348660
[TBL] [Abstract][Full Text] [Related]
12. Benzo(a)pyrenediolepoxide-hemoglobin adducts and 3-hydroxy-benzo(a)pyrene urinary excretion profiles in rats subchronically exposed to benzo(a)pyrene.
Bouchard M; Viau C
Arch Toxicol; 1995; 69(8):540-6. PubMed ID: 8534197
[TBL] [Abstract][Full Text] [Related]
13. In vitro to in vivo extrapolation of effective dosimetry in developmental toxicity testing: Application of a generic PBK modelling approach.
Fragki S; Piersma AH; Rorije E; Zeilmaker MJ
Toxicol Appl Pharmacol; 2017 Oct; 332():109-120. PubMed ID: 28760446
[TBL] [Abstract][Full Text] [Related]
14. Integrating in vitro chemical transplacental passage into a generic PBK model: A QIVIVE approach.
Fragki S; Hoogenveen R; van Oostrom C; Schwillens P; Piersma AH; Zeilmaker MJ
Toxicology; 2022 Jan; 465():153060. PubMed ID: 34871708
[TBL] [Abstract][Full Text] [Related]
15. Urinary excretion of benzo[a]pyrene metabolites following intravenous, oral, and cutaneous benzo[a]pyrene administration.
Bouchard M; Viau C
Can J Physiol Pharmacol; 1997 Mar; 75(3):185-92. PubMed ID: 9164700
[TBL] [Abstract][Full Text] [Related]
16. Correlation between biomarkers of polycyclic aromatic hydrocarbon exposure and electrophilic tissue burden in a rat model.
Tzekova A; Thuot R; Viau C
Arch Toxicol; 2004 Jun; 78(6):351-61. PubMed ID: 14749914
[TBL] [Abstract][Full Text] [Related]
17. Towards a generic physiologically based kinetic model to predict in vivo uterotrophic responses in rats by reverse dosimetry of in vitro estrogenicity data.
Zhang M; van Ravenzwaay B; Fabian E; Rietjens IMCM; Louisse J
Arch Toxicol; 2018 Mar; 92(3):1075-1088. PubMed ID: 29234833
[TBL] [Abstract][Full Text] [Related]
18. Predicting points of departure for risk assessment based on in vitro cytotoxicity data and physiologically based kinetic (PBK) modeling: The case of kidney toxicity induced by aristolochic acid I.
Abdullah R; Alhusainy W; Woutersen J; Rietjens IM; Punt A
Food Chem Toxicol; 2016 Jun; 92():104-16. PubMed ID: 27016491
[TBL] [Abstract][Full Text] [Related]
19. Effects of aloe, aloesin, or propolis on the pharmacokinetics of benzo[a]pyrene and 3-OH-benzo[a]pyrene in rats.
Cao D; Yoon CH; Shin BS; Kim CH; Park ES; Yoo SD
J Toxicol Environ Health A; 2005 Dec; 68(23-24):2227-38. PubMed ID: 16326436
[TBL] [Abstract][Full Text] [Related]
20. Development of a Combined In Vitro Physiologically Based Kinetic (PBK) and Monte Carlo Modelling Approach to Predict Interindividual Human Variation in Phenol-Induced Developmental Toxicity.
Strikwold M; Spenkelink B; Woutersen RA; Rietjens IMCM; Punt A
Toxicol Sci; 2017 Jun; 157(2):365-376. PubMed ID: 28498972
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
